Purpose To assess the safety and efficacy of neoadjuvant bevacizumab with standard chemoradiotherapy in locally advanced rectal cancer and explore biomarkers for response.
目的:评估在局部进展期直肠癌患者中联合贝伐单抗和标准放化疗的新辅助治疗有效性和安全性,并探索标志物反应。
Results Extended radical resection, neoadjuvant chemotherapy, orthotopic liver transplantation, photodynamic therapy and molecular chemoradiotherapy might improve the survival rate.
结果扩大根治切除、新辅助放疗化疗、原位肝移植、光动力学治疗和分子放化疗均能有效地提高患者的生存率。
应用推荐